oncology days - oeci · 3 oeci2016 oncology days the oeci is a non-governmental organisation...

B R U S S E L S - 2 0 1 6GENERAL-ASSEMBLY, SCIENTIFIC CONFERENCESAND-RELATED-EVENTS

Brussels, June 15th-17th 2016Sofitel Brussels Le Louise

Oncology Days

FIRSTANNOUNCEMENT

Organisation of European

Cancer Institutes

Official OECI Journal

DEVELOpING ThE FUTURE IN

COMpREhENSIVE CANCER CARE

ORGANISATION OF EUROPEAN CANCER INSTITUTES

EUROPEAN ECONOMIC INTEREST GROUPING

3838

OECI2016 ONCOLOGY DAYS

2

For the third time, the Directors of the European Cancer Institutes convene in Brussels, and I am honoured to have the privilege to host the OECI Oncology Days 2016 in my city, which I would like to thank in the name of all our Members for the generous support given to the event. The main objective pursued by OECI under my Presidency is to re-inforce and re-define the identity of our organisation through its distinctive gamut of activities on the European scene. Our focus is to continue to be Europe’s unique representative of cancer centres by way of inclusivity.OECI is an organisation of cancer institutes for cancer institutes, whose main activity is to promote the sharing and disseminating of ideas, best practices and efficient organisation of cancer research and care services. Our expertise in certification of quality, promoted by means of our Accreditation and Designation programme for cancer centres, is increasingly well-established and has been called upon recently, in order to help to define quality criteria within the Joint Action on Rare Cancers, launched into the European Health Programme 2014-2020. Our commitment to improve diagnostic competences through the medical pathology departments is growing and translates itself into a multi-pronged operation of excellence.The attention that our institutes dedicate daily to patients has led us to formalize a synergistic alliance with the ECPC, by the signing of a written agreement of collaboration, as well as by mapping out an ECPC-OECI Joint Declaration, that I will be very happy to present to our Members for their feedback.The increase in survivorship has also reinforced the issue of patient rights to access the best options for a cure and therapeutic solutions, so as to resume a dignified and active life in society, post illness. The best ways to offer such supports to patients through our institutes need to be reached with the help of ECPC and the OECI’s Working Group on Palliative Care, which participates in the group of experts coordinated by the OMS.We are also seeking to raise consciousness of our Members about the conditions of some of our colleagues working in less favourable economic regions, faced by a scarcity of financial and technological resources. This prompted us to begin a collaboration with the International Union Against Cancer. In recent years, the fast paced progress of science and technology has brought radical change to the structure of our Institutions, in order to meet the needs that a personalised medicine now requires. The immunology approach to cancer care is a practical example of how our Institutions and the oncologists must continuously re-think their approach to therapy and to the internal organisation of the cancer centres. There is a mandatory need to be prepared given the growing number of cancer patients and different types of treatments that we are able to offer them today. We need to think about how to organise clinical immunology and integrate it in the multidisciplinary approach to our patients, with more interactions between lab and clinic and with the inclusion of non-oncologist specialists to fight the unusual adverse reactions to immunotherapy medication.The OECI membership should be seen as an investment that will increasingly become a two way process, in which the Institutes play a proactive and collaborative role, and where the diversity represents our wealth and our strength. The 2016 Oncology Days marks the 38th convening of the Directors of European Cancer Centres. This is a solid example of the dedication and efforts made by the OECI and its Members in the promotion of a sustainable progress, with the aim of improving the level of care and giving patients from all walks of life equal access to the best quality of cancer care. W

EL

CO

mE

tO

th

E O

EC

I O

NC

OL

OG

Y D

AYS

2016

Welcome to the OECI Oncology Days 2016

3


The OECI is a non-governmental Organisation founded in Vienna, in 1979.

The primary objectives of its 70 Members are to reduce fragmentation and to give all European cancer patients the possibility of receiving the best available care. The OECI Members have established themselves in the innovation frontline by tailoring solutions to the individual patient, by gaining in efficiency and efficacy and with the potential to transform the way healthcare is delivered today.

To better achieve its goals, the Organisation works in close collaboration with the European Cancer Patients Coalition.

The OECI goals are achieved by promoting and strengthening the concept of Comprehensive Cancer Centres in Europe in order to improve quality in cancer care and translational research, as well as from an organisational viewpoint. In an effort to efficiently contribute towards an increase in the quality of care, about 50% of all OECI Members are already participating in the OECI Accreditation/Designation programme.

In the current year, some of the already certified Centres will be re-visited in order to confirm their Designation status, according to the revised quality standards for comprehensive and multidisciplinary cancer care in European cancer centres, as published in the Second Edition of the OECI Accreditation and Designation User Manual. So far, 32 European wide, comprehensive and clinical cancer centres have taken part in the OECI Accreditation & Designation programme.

The OECI interacts with its members in the definition of tasks of international and common interest. The common goal is to facilitate member participation in European projects and programmes, to support training activities on forefront topics, which provides a sound basis for accelerated development of expertise and future collaborative work. This in turn attracts professionals and officers from across disciplines and ultimately underlines the value of multidisciplinary actions.

Giving the crucial role to pathology departments in oncology and the expected “influx” of new markers and diagnostics, the OECI acts in close cooperation with the European Association for Cancer Research and the European Society of Pathology, in order to better disseminate the innovation process amongst its members and abroad. The EACR-OECI training course series on “Molecular Pathology Approach to Cancer” in Amsterdam, is just an examples of the OECI efforts to promote the dissemination of innovation.

Managerial support is mainly organised through the President’s Office and the Central Office in Brussels, alongside the Liaison and Director’s Office in Genoa. You can find more information about the Organisation at www.oeci.eu <http://www.oeci.eu>. The dissemination of the OECI activities, reports, proceedings are also publicized through ecancermedicalscience, the Official OECI e-Journal at <http://www.ecancer.org>.

Introduction to the OECI

INt

RO

DU

Ct

ION

tO

th

E O

EC

I


4

th

E O

EC

I B

OA

RD

/ W

OR

KIN

G G

RO

UP

AN

D A

Ct

IVIt

IES

Working Groups and ActivitiesBiobanks and Molecular Pathobiology Giorgio StantaTrieste, Italy

Palliative Care Massimo CostantiniReggio Emilia, Italy

START-OECI Lisa LicitraMilan, Italy

Accreditation and Designation Simon OberstCambridge, United Kingdom

Cost - Benefit Wim H. van Harten Amsterdam, The Netherlands

Past PresidentWim H. van Harten Amsterdam, The Netherlands

Treasurer José Maria Laranja Pontes Porto, Portugal

Elected MemberJozsef LöveyBudapest, Hungary

Elected MemberGunnar SæterOslo, Norway

the OECI Board

Communication and Dissemination Gordon McVie Milan, Italy

Claudio Lombardo Genoa, Italy

President Dominique de ValeriolaBrussels, Belgium

Executive Secretary Marco A. PierottiMilan, Italy

Elected MemberCarlos CaldasCambridge, United Kingdom

Elected MemberChristof von KalleHeidelberg, Germany

OECI Central Office Guy StormeBrussels, Belgium

OECI DirectorClaudio LombardoGenoa, Italy

5


th

E O

EC

I Q

UA

LIt

Y N

Et

WO

RKthe OECI Quality Network

OECI Members A&D certified OECI Members in the A&D process Other OECI Members Non - OECI Members in the A&D process


6

the OECI membership t

hE

OE

CI

mE

mB

ER

ShIP

Austria•Comprehensive Cancer Center Graz,

Graz •Comprehensive Cancer Center Vienna,

Wien •Zentrum für Tumorerkrankungen

Linz Onkologisches Leitspital für Oberösterreich, Linz

BelgiumInstitut Jules Bordet (IJB), Brussels Kankercentrum Brussel, BrusselsAZ Groeninge, Kortrijk •Institut Roi Albert II, BrusselsCroatia•University Hospital for Tumors -

University Hospital Centre Sestre Milosrdnice, Zagreb

Czech RepublicMasarykuv onkologický ústav, Brno •Institut biostatistiky a analýz Lékarské a Prírodovedecké fakulty Masarykovy university, Brno Denmark•Kræftens Bekæmpelse Center for Kræftforskning, Copenhagen EstoniaSihtasutus Tartu Ülikooli Kliinikum, Tartu•North Estonia Medical Centre, Tallin FinlandHYKS Syöpäkeskus Helsinki University, HelsinkiFranceGustave Roussy, Villejuif Centre Leon Berard, Lyon•Institut Curie, Paris •Centre de Lutte Contre le Cancer Paul Strauss, Strasbourg •Centre Henri Becquerel, Rouen Germany•Deutsches Krebsforschungszentrum

(DKFZ), Heidelberg

•Universitäts KrebsCentrum Dresden, Dresden

•Charité Comprehensive Cancer Centre, Berlin

HungaryOrszágos Onkológiai Intézet, Budapest•National Koranyi Institute of TB and Pulmonology, BudapestItalyCentro di Riferimento Oncologico, Istituto Nazionale Tumori, Aviano IRCCS Azienda Ospedaliera Universitaria San Martino - IST - Istituto Nazionale per la Ricerca sul Cancro, GenovaIstituto Europeo di Oncologia, Milano Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, MilanoIstituto Nazionale Tumori Regina Elena, Roma Istituto Oncologico Veneto IRCCS-IOV, Padova Istituto Tumori Giovanni Paolo II, Istituto di Ricovero e Cura a Carattere Scientifico, BariIstituto Nazionale Tumori IRCCS “Fondazione G.Pascale” (INT-Pascale), Napoli IRCCS, Centro di Riferimento

Oncologico della Basilicata (CROB), Rionero in VultureAzienda Ospedaliera Arcispedale S. Maria Nuova IRCCS, Reggio Emilia •Ospedale San Raffaele (OSR), Milano •European School of Oncology (ESO),

Milano•IFOM - FIRC Institute of Molecular

Oncology, Milano•Istituto Scientifico Romagnolo per lo

Studio e la Cura dei Tumori [IRST]-IRCCS, Meldola-Forlì

7


th

E O

EC

I m

Em

BE

RSh

IP

•IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milano

•Ente Ospedaliero Ospedali Galliera, Genova

•Nerviano Medical Sciences Group S.r.l., Nerviano

Lithuania National Cancer Institute, Vilnus NorwayOslo Universitetssykehus (OUS), NorwayPoland•Wielkopolskie Centrum Onkologii,

PoznanPortugalInstituto Português de Oncologia do Porto FG, EPE, Porto Instituto Português de Oncologia de Lisboa FG, EPE, Lisbon Instituto Português de Oncologia de Coimbra FG, EPE, Coimbra RomaniaThe “Prof. Dr. Ion Chiricuta” Institute of Oncology (IOCN), Cluj •SC RTC Radiology Therapeutic Center

– Amethyst Radiotherapy, Otopeni Russia•Tatarstan Cancer Center “TCC”, Kazan•N.N. Blokhin Russian Cancer Research Centre, Moscow•P.A. Herzen Moscow Cancer Research Institute, MoscowSerbia•Institute of Oncology (IOV) Sremska

Kamenica Novi Sad, Sremska KamenicaSlovakia•Ústav experimentálnej onkológie SAV,

Bratislava Slovenia•Onkološki inštitut Ljubljana, LjubianaSpainFundación Instituto Valenciano de Oncología IVO Foundation, Valencia

•Institut Català d’Oncologia, Barcelona•Instituto Madrileño de Oncología

(Grupo IMO), Madrid Sweden•Karolinska Institutet, Stockholm The NederlandNetherlands Cancer Institute, Amsterdam•Erasmus MC Kanker Instituut, Rotterdam•IKNL Integraal Kankercentrum

Nederland, Utrecht•Maastricht University Medical Centre, Maastricht•Radboudumc Centrum voor Oncologie, Nijmegez Turkey•Dokuz Eylül Üniversitesi Onkoloji

Enstitüsü, IzmirUkraine•RE Kavetsky Institute of Experimental

Pathology, Oncology and Radiobiology (IEPOR), Kiev

United KingdomThe Christie NHS Foundation Trust, ManchesterCambridge Cancer Centre, CambridgeKing’s Health Partners Integrated Cancer Centre, London•Imperial College Healthcare NHS Trust, London

Non-OECI members in the A&D processDenmark Vejle Cancer Hospital, VejleTurkey Anadolu Medical Centre, Kocaeli, Italy Humanitas Cancer Centre, Milan


8

the OECI 2016 Oncology Days Tuesday June 14th - Afternoon

• ExtendedBoardMeeting Room Elephant

Wednesday June 15th - All day

• PathologyDay Clinical Research and Applied Oncology: an integrated and indissoluble process Room Metamorphose Thursday June 16th - All day

•ScientificConference Cancer Immunotherapy: from lab to clinical

applications - Potential impact on cancer centres Organisation

Room Metamorphose

Thursday June 16th - Afternoon

• Bench-CanProjectFinalConferencer Room Jungle

Friday June 17th - Morning

•OECIGeneralAssembly2016 Room Jungle

Social events June 14th - Evening

• PathologyandBoardDinner Sofitel – Le Crystal Lounge and Restaurant (restricted to invited speakers and participants to the Pathology

Day)

June 15th - Evening

• Bench-CanDinner June 16th - Evening

• OECI2016GalaDinner anddeliveryoftheOECI2016CancerPrize Guided Visit to the Musée Magritte and Gala Dinner at Salle Magritte (restricted to OECI members and invited participants)

th

E O

EC

I 20

16 O

NC

OL

OG

Y D

AYS

Onc

olog

y D

ays

prog

ram

me

9


GE

NE

RA

L t

ImE

tAB

LE

17June2016

MO

RNIN

G

15June2016

AFTE

RNO

ON

General timetable

OECI Pathology DayClinical Research

and Applied Oncology:

an integrated and indissoluble process

Room Metamorphose

Lunch

EVEN

ING

16June2016

Gala Dinner

Lunch

Departure of the Delegates

Scientific Conference

Cancer Immunotherapy:

from Lab to Clinical Applications -

Potential Impact on Cancer Centres

Organisation

Room Metamorphose

OECI2016General

Assembly

Room Jungle

Scientific Conference

Cancer Immunotherapy:

from Lab to Clinical Applications -

Potential Impact on Cancer Centres

Organisation

Room Metamorphose

Lunch

OECI Pathology DayClinical Research

and Applied Oncology:

an integrated and indissoluble process

Room Metamorphose

14June2016

BenchCan Dinner

Extended Board Meeting

Room Elephant

Joint Pathology and Board

Dinner


10

June 15th

Sofitel BrusselsLe Louise

Room Metamorphose

OECI Pathology DayClinical Research and Applied Oncology: An integrated and Indissoluble Process

Rationale1. Avoiding irreproducibility of clinical research.2. Accelerating time for biomarker validation to give to Oncology Excellence Centres

more opportunities to have better prognosis and treatment for patients.3. Improving the European organization to use clinical tissues profitably.4. Pointing out that today clinical research is completely integrated with practical medical

application.

The above goals are supported by the following activities developed by several European Cancer Organisation:– Organisation of the European Institutes - Accreditation and Designation Programme

(OECI A&D)– European Infrastructures for Biobanks and Molecular resources (BBMRI-ERIC) and

Archive Tissues – Working Groups of the European Society of Pathology (ESP) to standardize analysis

methods, to improve preanalytical conditions of tissues and to manage tumour heterogeneity

PRELIMINARY PROGRAMME

Morning session

09.00-09.30 INTRODUCTION: COLLABORATION BETWEEN PATHOLOGISTS AND ONCOLOGISTS

09.30-11.00 CLINICAL RESEARCH AND APPLIED ONCOLOGY Speakers to be confirmed

09.30-10.00 Clinical Research and Oncology Speakers to be confirmed

10.00-10.30 Clinical Research, a BBMRI Model Speakers to be confirmed

10.30-11.00 Coffee Break

11.00-11.30 Applied Clinical Models Speakers to be confirmed

11.30-12.00 Clinical Research and Industry Speakers to be confirmedPA

th

OL

OG

Y D

AY

11

OECI2016 ONCOLOGY DAYSJune 15th


Room Metamorphose

OECI Pathology DayClinical Research and Applied Oncology: An integrated and Indissoluble Process

12.00-12.30 CLINICAL RESEARCH: INTERACTION BETWEEN RESEARCHERS, PATHOLOGISTS AND ONCOLOGISTS

12.00-12.30 Clinical Verification and Validation of Research: the Example of HERCULES Project on Ovary

Speakers to be confirmed 12.30-12.50 Short Presentation of the activities of the on-line

journal “ecancer” Speakers to be confirmed

13.00-14.00 Lunch

Afternoon session

14.00-14.30 Clinical Research Development in Colorectal Cancer Speakers to be confirmed

14.30-15.00 Clinical Research in Breast Cancer Speakers to be confirmed

15.00-15.30 Clinical Research in Lung Cancer Speakers to be confirmed


16.00-18.00 CLINICAL RESEARCH ETHICS

16.00-16.30 The Central Position of the Patient Speakers to be confirmed16.30-17.00 Tissues and Ethics Speakers to be confirmed17.00-17.30 Ethics and Clinical Research Speakers to be confirmed17.30-18.00 Ethics and Privacy Protection Speakers to be confirmed

18.00-18.45 GENERAL DISCUSSION

PAt

hO

LO

GY

DAY


12

Scientific Conference Cancer Immunotherapy: from Lab to Clinical Applications - Potential Impact on Cancer Centres Organisation

09.00-09.20 Welcome by the OECI President Dominique de Valeriola

09.20-10.00 Opening Lecture given by the Winner of the OECI OncologyPrize2016

Speaker to be confirmed

Session 1: The laboratory background and current developments

10.00-10.30 The experimental evidence for immune-mediated cell death during chemotherapy and radiotherapy


10.30-11.00 Technologies and current translational approaches in immunotherapy



11.30-12.00 Adoptive Cellular Therapy approaches and early clinical results


12.00-12.30 Biomarkers of immune response Speaker to be confirmed

12.30-13.00 DISCUSSION

13.00-14.00 Lunch

SCIE

Nt

IFIC

CO

NF

ER

EN

CE

June 16th


Room Metamorphose

13

OECI2016 ONCOLOGY DAYSScientific Conference Cancer Immunotherapy: from Lab to Clinical Applications - Potential Impact on Cancer Centres Organisation

June 16th


Room Metamorphose

SCIE

Nt

IFIC

CO

NF

ER

EN

CE

Session 2: Clinical Immunotherapy and Combinations

14.00-14.30 Immune checkpoint inhibitors and combination approaches: current status and future perspectives


14.30-15.00 Combining radiotherapy and cancer immunotherapy: a paradigm shift?



15.30-16.00 Cancer vaccines: still a viable approach? Speaker to be confirmed

16.00-16.30 Implications of modern immunotherapy on the organisation of healthcare in cancer centres


16.30-17.00 DISCUSSION AND CLOSING


14

Counting 7 Partners, 11 Pilot Sites and the European Cancer Patients Coalition, under the coordination of the OECI, the Bench-Can project aims to improve quality of cancer patient’s treatment.

With an ageing population, the burden that cancer will impose on our society is likely to increase. Cancer has replaced cardiovascular diseases as the leading cause of premature death in 28 out of 53 European countries, becoming the leading cause of death. In this framework, and in the light of an highly affecting cost-benefit analysis, the Bench-Can project focuses on identifying how European providers can be assisted in order to improve services to the patients, reduce care provision inequalities, and raise a better quality of oncologic services.

The partnership of the project challenges two key topics:1. ensuring an active engagement of European comprehensive cancer centres, clinical

centres, cancer departments and units;2. sustain the quality of treatments and outcomes of the operating environments for health

services which have to adapt to co-morbidities of an ageing population, speed the technology development and related financial constraint, and reduce differences in health systems performances within EU countries.

The 11 Bench-Can Pilot Sites help to define:– the description of a cancer care organisation using an agreed number of indicator sets

describing the comprehensive care context; – the modeling performance of comprehensive cancer centres or cancer departments/units

at general hospitals, by several matrices (e.g. organizational objectives/intermediaries; staff/teams; intermediaries/services; services/patient outcome enablers; translational research or medicine-related data).

Detail analyses will be performed on all Pilot Sites, for instance using data envelopment techniques and, in particular, visiting the centres with a restricted group of specialists in order to define and refine a final Benchmarking Tool that focuses on operations management and best clinical practices and which will be available and applied to all interested institutes/hospitals in Europe.

The expected Bench-Can final outcomes are:(i) two benchmark tools planned for use in comprehensive cancer centres & cancer

departments/units at general hospitals; (ii) the identification of areas for improvement for quality of care & patient outcomes with

advanced plans adopted by the pilot sites, at first, and by a broader audience in the coming years;

(iii) a benchmark manual with budget impact formulae for free access so to permit betterments in the management of cancer centres;

(iv) a roadmap for future assessments of comprehensive cancer care.

At the end of the project, we expect the Bench-Can tools to be adopted as a non-profit service available to cancer centres and services across the EU.

INt

RO

DU

CIN

G B

EN

Ch

-CA

N

15


Final meeting

14.00-14.10 Welcome Wim van Harten

14.10-14.40 Experiences with Benchmarking in Europe (development and tool)

Speakers to be confirmed

14.40-15.10 Introduction final/adapted BENCH-CAN tool and Manual related to experiences and results



15.30-16.00 Experiences with Benchmarking in the US (outcomes)


16.00-16.30 Outcomes of the BENCH-CAN project (Qual, Quan, CQI) Speakers to be confirmed

16.30-17.00 Experience and action/improvement plans pilot site Institutional (Porto, Budapest)


17.00-17.15 Future possibilities/sustainability Speakers to be confirmed

17.15-17.50 Moderated discussion Chair: Wim van Harten • BenchCan Manual • Pilot site Institutional • Pilot site Pathway 17.50-18.00 SUMMARY OF MAIN DISCUSSION AND ACTION

POINTS AND CLOSING

BE

NC

h-C

AN

PR

OJE

Ct

June 16th


Room Jungle

Project


16

38ORGANISATION OF EUROPEAN CANCER INSTITUTES


38 June 17th


Room Jungle

General Assembly

08.00 Registration

08.15 General Assembly Constitution, welcome and approval of the Agenda Chairperson: Dominique de Valeriola

08.30 Session1: Administrative and financial matters Chairperson: Dominique de Valeriola

Point1: ApprovalofMay2015GeneralAssembly’sMinutes(vote requested – decision taken at the simple majority of the OECI Full Memberspresentorrepresented)–AnnextoPoint1.

Dominique de Valeriola

Point2: ApprovaloftheFinancialStatement2015(voterequested- decision taken at simple majority of the OECI Full Members presentorrepresented)–AnnextoPoint2

José Laranja Pontes Point 3:2016and2017ProvisionalBudget(onlyfor2016budgetthe

vote is requested – decision taken at simple majority of the OECI Full Members present of represented) – Annexes to Point 3

José Laranja Pontes

Point4: OECIBoardcomposition2016update(votenonrequested) –AnnextoPoint4


Point5:Working Groups and Co-opted Board Members update (vote not requested)–Annextopoint5


Point6:OECIMembership–AnnexestoPoint6 Claudio Lombardo 6.1 New applications for membership (vote requested for full

membership, decision taken at unanimity of the OECI Full Members present or represented; for associated membership, by simple majority of the OECI Full Members present or represented). 6.2Requestsof1MembertobedismissedfromtheOECI membership (vote not requested). 6.3 Proposal for discontinuing from the membership of OECI Members (vote requested - decision taken at two-thirds majority of the OECI Full Members present or represented).

GE

NE

RA

L A

SSE

mB

LY

17


GE

NE

RA

L A

SSE

mB

LY

Ceremony for the delivery of the OECIAccreditationCertificates2016Dominique de Valeriola and Simon Oberst

10.30 Coffee break

11.00 Session2: The OECI Strategy and Working Groups Activities Chairperson: Dominique de Valeriola

Point7: The ECPC-OECI proposal of ECPC-OECI Joint Declaration Proposal Point 8: OECI future strategies 8.1 Accreditation & Designation and the Joint Action on Rare Cancers Simon Oberst 8.2Biobanks and Molecular Pathobiology Giorgio Stanta 8.3 Health Economics WG and BenchCan Project Wim H. van Harten 8.4Palliative Care Massimo Costantini 8.5Communication and dissemination Gordon Mc Vie

Point 9: Venues of the General Assemblies for the coming years and closure of the G.A. Dominique de Valeriola

13.00 Lunch

June 17th


Room Jungle

General Assembly 38ORGANISATION OF EUROPEAN CANCER INSTITUTES


38


18

General information about BrusselsAIRPORT AND TRANSPORTATIONBrussels International Airport Belgium’s main airport is located in Zaventem, 12 km north of Brussels. From this airport, you can reach Brussels by train or bus. Taxis are also readily available. An average taxi ride to the centre of Brussels costs €40.

Brussels Charleroi-Sud Airport This subsidiary airport is located 46 km South of Brussels and is similarly accessible by train, bus and taxi. An airport shuttle departs every 30 minutes from the airport to take passengers to the Brussels South railway station.

TaxiIf you want to take a taxi in Brussels there are several companies to choose from:Autolux: +32 (0)2 411 12 21Taxis Bleus: + 2 (0)2 268 00 00Taxis Orange: +32 ((0)2 349 43 43Taxis Verts: +32 (0)2 349 49 49

CLIMATEIn June, you can expect an average low of 11°C, and an average high of 20/25°C. Bring your umbrella!

GE

NE

RA

L I

NF

OR

mAt

ION

AB

OU

t B

RU

SSE

LS

GENERALINFORMATIONABOUTTHEOECI2016ONCOLOGYDAYS

Registration and attendance to the OECI 2016 Oncology Days is free. Coffee breaks and lunches are provided during the meetings.

Those interested in participation to the Scientific Sessions are invited to te send an email to [email protected] indicating full name, home institution and symposium to which they intend to register.

The participation to the Social Events is under invitation and the OECI 2016 General Assembly is rescricted to the OECI members.

The official language is English. No simultaneous translation in other languages will be provided during the sessions.

19

OECI2016 ONCOLOGY DAYSmusée magritte Located in the heart of Brussels, the Magritte Museum presents an outstanding collection of works by the Belgian Surrealist artist René Magritte. This rich collection of over 200 works is the largest in the world.Multidisciplinary, the museum consists of paintings (Empire of Light, The Man from the Sea, The Domain of Arnheim), gouaches, drawings, sculptures and painted objects, but also billboards, music scores, old photographs and films directed by Magritte himself. In the late Twenties, René Magritte, one of a small group of Brussels iconoclasts, started to make a name for himself with his deep questioning of traditional pictorial language, rapidly becoming a main protagonist of the Surrealist movement, in Belgium and abroad.The setting up of this museum, containing works belonging to the Royal Museums of Fine Arts of Belgium or from deposits of private collectors and public institutions, was made possible by the skills sponsorship of the French and Belgian subsidiaries of ENGIE and the support of the Magritte Foundation.

mU

SéE

mA

GR

Itt

E


20

Sofitel Brussels Le Louise TheOECIOncologyDays2016willtakeplaceattheSofitelBrusselsLeLouise,aluxurious5-starhotellocatedintheexclusiveAvenueLouisedistrict.RoomsareavailableataspecialOECI2016rateforguestsuntilMay13th2016.

For reservation please click on the link below: www.oeci.eu/Attachments/Reservation_form_OECI.pdf

This central location is ideal for a walk along historical buildings and streets: in few minutes from the hotel it’s possible to visit the beautiful Egmont Park or the Sablon area with the Notre Dame Chapelle, the Royal Museums of Fine Arts of Belgium, the Cathedral of St. Michael and St. Gudula or the Royal Palace.The Sofitel le Louise has been designed by the famous Portuguese designer, architect, artist and top chef Antoine Pinto* to reflect light and create a theatrical and stylish atmosphere.

*By the year 1981, the Besser Guide (the German equivalent of the Guide Gault-Millau) proclaimes Antoine Pinto one of Central Europe’s hundred best chefs.

Other hotels close to the site of the OECI Oncology Days:

The Hotel Brussels www.thehotel.be

Hotel Chambordwww.hotel-chambord.be

NH Brussels City Centrewww.nh-hotels.com

Thon Hotel Bristol Stephaniewww.thonhotels.com

Pentahotel Brussels City Centrewww.pentahotels.com

Fondation Universitairewww.fondationuniversitaire.be SO

FIt

EL

BR

USS

EL

S L

E L

OU

ISE

21


NO

tE

S


22

NO

tE

S

23


THEOECI2016SCIENTIFICCOMMITTEEPresidents: Dominique de Valeriola and Gunnar SæterMembers: Carlos Caldas, Wim van Harten, Marco A. Pierotti,José Laranja Pontes, Jozsef Lövey, Giorgio Stanta, Guy Storme, Christof von Kalle

THEOECI2016LOCALORGANISINGCOMMITTEE Jean Benoit Burrion - Institut Jules BordetBjörn Snyckers - UZ BrusselMaria Cummins - Institut Jules BordetVan de Werve Ariane - Institut Jules BordetSara Barbosa - Sofitel Le LouiseCaroline Harake - Musée royaux des Beaux-Arts de Belgique

THEOECI2016ONCOLOGYDAYSSECRETARIATSBRUSSELS: Lutgarde D’HawersGENOA: Germana Gianquinto, Giorgia Pesce, Patrizia SommellaTRIESTE: Valentina Melita

OECI2016ONCOLOGYDAYSCOORDINATINGOFFICE Claudio Lombardo - OECI DirectorTel: +32 2 512 01 46 Email: [email protected]

ORGANISATION OF EUROPEAN CANCER INSTITUTES


3838 ESO Recommended

The Oncology Days are co-financed by the European Commission through:

BenchCan Project “Grant Agreement 2012 12 11”

Co-funded bythe Health Programmeof the European Union

ACKNOWLEDGMENTSThe OECI 2016 Oncology Days are made possible thanks

to the generous contribution of OECI, the Brussels City Hall, the Institut Jules Bordet

and the UZ Brussel.

oncology days - oeci · 3 oeci2016 oncology days the oeci is a non-governmental organisation...

Documents